Zhejiang Tianyu Pharmaceutical(300702.SZ): Apatamine API passes CDE review.

Tianyu Group (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Jingsheng Pharmaceutical Co., Ltd. ("Jingsheng Pharmaceutical") recently passed the evaluation of abiraterone raw materials by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Abiraterone is a non-steroidal antiandrogen used for the treatment of prostate cancer. It works by inhibiting the androgen receptor signaling pathway to slow down disease progression. It is mainly used for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and should be used in conjunction with castration therapy under the guidance of a doctor.